Overview

Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

Status:
Not yet recruiting

Trial end date:
2025-07-22

Target enrollment:

Participant gender:

Summary

This is a a phase 1, open label study to assess the safety and efficacy of ThisCART19 (Allogeneic CAR-T targeting CD19) Bridging Hematopoietic Stem Cell Transplantation in patients with refractory or relapsed B cell acute lymphoblastic leukemia (r/r B-ALL).

Phase:

Phase 1

Details

Lead Sponsor:

Fundamenta Therapeutics, Ltd.

Collaborator:

The First Affiliated Hospital of Zhengzhou University

Treatments:

Cyclophosphamide
Etoposide
Fludarabine